Abstract: The invention relates to a protein comprising a plurality of conserved peptide sequences, or variants thereof, wherein at least one of the conserved sequences is conserved across all four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4, and wherein the conserved sequences comprise at least part of a sequence of one or more non-structural proteins of the dengue virus serotypes. The invention further relates to associated peptides, compositions, nucleic acids, viral vectors, virus-like particles, use, prime boost vaccination kits, agents and methods.

Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.

Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.

Abstract: The present disclosure provides certain combinations of immunogenic compositions against HSV-2 and antiviral therapy. The vaccines can be used therapeutically and/or prophylactically.

Abstract: The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.

Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.

Abstract: The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine recipients, and methods for improved vaccination strategies are presented.

Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Abstract: Compositions and methods for treating one or more symptoms one or more symptoms such as reduced sexual desire and fecal compaction are provided. Accordingly, the disclosed composition can be administered to subjects in need thereof, including patients with multiple sclerosis, particularly in patients in which multiple sclerosis symptoms are exacerbated in the premenstrual time period/during the menstrual period. The compositions are unit dosage forms including pharmaceutically acceptable salts of a BPC peptide. The unit dosage forms can be formulated for enteral, parenteral, or topical administration. Also provided herein are methods of increasing sexual desire or reducing fecal compaction in a subject in need thereof. In one embodiment, the compositions disclosed herein are used to alleviate one or more symptoms in patients with multiple sclerosis, particularly in patients in which multiple sclerosis symptoms are exacerbated in the premenstrual time period.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Abstract: Radiopaque hydrogels, in particular radiopaque hydrogel microspheres, comprising a polymer having 1,2-diol or 1,3-diol groups acetalized with radiopaque species.

Abstract: Chewable gelatin formulations that include a bovine gelatin and a fish gelatin.

Abstract: The present application is directed to a dental material and a method of using the dental material. The dental material can include a hardenable resin; an initiator system; a filler; and from about 1 wt % to about 20 wt % zinc compound, based on the weight of the hardenable resin. The contrast ratio of the cured dental material increases by at least about 10 units after continuous exposure to an aqueous solution for 21 days.

Abstract: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.

Abstract: The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.

Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.

Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

Abstract: The invention relates to synthetic polynucleotides encoding fukutin related protein (FKRP). The invention further relates to nucleic acid constructs comprising the synthetic polynucleotides and methods of using these synthetic polynucleotides to treat dystroglycanopathy disorders.

Abstract: Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.

Abstract: A method for in vivo RNA or protein expression is provided. The method includes introducing a double-stranded concatemeric DNA into a eukaryotic cell to generate a desired RNA or protein. The double-stranded concatemeric DNA includes a plurality of tandem repeat sequences, wherein each of the plurality of tandem repeat sequences comprises an expression sequence. The double-stranded concatemeric DNA comprises one or more phosphorothioated nucleotides, wherein a ratio of phosphorothioated nucleotides to total nucleotides in the double-stranded concatemeric DNA is at least 1:1600. A eukaryotic cell comprising an exogeneous, double-stranded concatemeric DNA comprising the plurality of tandem repeat sequences is also provided.

Abstract: A molecular probe for use in the detection of myelin in a subject includes a compound having the general formula selected from the group consisting of: formula (I), and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.

Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.

Abstract: Iohexol particles, contrast agent compositions comprising iohexol particles, methods of preparing iohexol particles, and methods of administering iohexol particles are provided herein. The iohexol particles of the present invention substantially dissolve in water within about 60 seconds when tested using Modified United States Pharmacopeia Method 641.

Abstract: The present invention relates to magnetic contrast structures for magnetic resonance imaging, and methods of their use. The contrast structures include magnetic materials arranged as a pair of disk-shaped magnetic components with a space between a circular surface of each disk shape, or a tubular magnetic structure, a substantially cylindrical magnetic structure, a substantially spherical shell-formed magnetic structure, or a substantially ellipsoidal shell-formed structure, each defining a hollow region therein. The space and/or hollow region in the contrast structure creates a spatially extended region contained within a near-field region of the contrast structure over which an applied magnetic field results in a homogeneous field, such that nuclear magnetic moments of a second material when arranged within the spatially extended region precess at a characteristic Larmor frequency, whereby the contrast structure is adapted to emit a characteristic magnetic resonance signal of the magnetic material.

Abstract: Disclosed are a targeting aptamer for atherosclerosis and a preparation method and application thereof. The targeting aptamer is a targeting aptamer fragment for atherosclerosis obtained through screening of macrophage-derived foam cells together with reverse screening of smooth muscle cells, endothelial cells, and THP-1 cells using a SELEX method; and the use of the targeting aptamer in preparation of an MRI targeting nano-contrast agent for atherosclerosis allows the specific binding of the MRI targeting nano-contrast agent for atherosclerosis only with the macrophage-derived foam cells, and allows high specific binding thereof with vascular tissues with AS lesion, this improving targeting effect of the MRI targeting nano-contrast agent for atherosclerosis and realizing early specific diagnosis of arterial sclerosis.

Abstract: A process for preparing a composition comprising encapsulated gas microbubbles, the process comprising: providing an aqueous protein solution of a heat-denaturable protein at a temperature necessary to achieve incipient denaturation; heating a gas by using heat from the heated protein solution; mixing the heated gas and the heated protein solution to obtain a gas/liquid mixture; and dispersing the gas into the protein solution by subjecting the gas/liquid mixture to mechanical shear forces to form a composition of gas microbubbles encapsulated by denatured protein.

Abstract: The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.

Abstract: Provided is an autoclave. The autoclave includes a sterilization chamber, a steam generator including a heat conductor housed in the sterilization chamber and including a vaporization duct for the sterilization fluid, connectors configured to connect the vaporization duct and the sterilization chamber in a fluidic through connection, and a heater configured to heat the heat conductor by vaporizing the sterilization fluid in the vaporization duct.

Abstract: A seal arrangement for sealing a space between a sterilization unit and adjacent walls in order to separate first and second rooms has a double seal gasket arrangement with a seal chamber there within. The seal chamber may be pressurized with a fluid and then the pressure within the seal chamber monitored by a pressure sensor. The double seal assembly provides an arrangement which can give an indication of the quality of the seal in order to detect any leakage and a more secure seal around the sterilization unit and as a result secure separation between a sterile or contaminated room and a general hospital area.

Abstract: A method and device for high-pressure, high-temperature steam sterilization of endoscopes includes pressure resistant fittings to attach a steam generator to the ports of an endoscope. The method and device allows for high-pressure, high-temperature steam to circulate throughout the endoscope, exposing various surfaces to steam for sterilization. The method and device also allows for high-pressure, high-temperature steam to circulate selectively through the channels of the endoscope, selectively sterilizing the channels and allowing for use of this method with current high-level disinfection methods. The method and device also allows for movement of the scope elevator channel during the sterilization process, allowing for steam to reach the crevices around the elevator and other moving parts of an endoscope.

Abstract: Liquid water detection in a sterilization chamber that can distinguish liquid water from material in the load that is outgassing and can dry the liquid, is independent of the vacuum pump and chamber leak rate, and that is capable of detecting small amounts of liquid and drying the liquid without freezing the liquid in the process is achieved by monitoring conditions in the chamber at two different pressures, one above the boiling point of water and another below the boiling point of water at a given load temperature.

Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.

Abstract: An assembly for evaporating a volatile fluid is described, the assembly comprising a device and a refill which are detachable from one another: wherein the device comprises a magnetic induction coil configured to operate with an alternating current passed therethrough; and wherein the refill comprises a reservoir for the volatile fluid, a volatile fluid transport means to draw the fluid from the reservoir, and at least one susceptor arranged to heat the volatile fluid transport means when said alternating current is passed through the induction coil. Refills, devices and methods of operation are also described.

Abstract: An automatic dispensing device for volatile fluid operable to apply one or more agent to a local environment for more than 14 days. Preferred devices dispense a first agent for air freshening, and may optionally dispense a second agent, such as a drain cleaner. A workable drain cleaner is structured to permit a slow release of drain cleaning agent. A dispensing device may nonexclusively operate by evaporation of volatile fluid from a polymer or rubber-like carrier material that is infused with the volatile fluid; gravity-induced drip from a bulk supply of volatile fluid through a small orifice onto an emanator; osmotic transfer of volatile fluid from a bulk supply; gas-pump drive of volatile fluid at controlled pressure; or diffusion of volatile fluid through a wall of a container of bulk volatile fluid; and combinations thereof.

Abstract: An emanator device for emanating an air treatment agent into the surrounding air comprises a housing which contains a solid or liquid source of the air treatment agent, wherein the housing comprises a blister or capsule containing an air treatment agent and a plurality of openings which are sufficiently small that they can be closed by a film or plug of water. For example the openings may be provided by a gauze or mesh. The openings do not inhibit the emanation of air treatment agent released from the blister, but when the emanator device is subject to wet conditions, as may happen in a dishwashing machine, the openings are blocked by a film or plug of water. The air treatment agent does not therefore enter the water, where it may have caused adverse effects, or simply have been wasted. Under dry conditions, however, emanation occurs normally.

Abstract: A microfluidic cartridge and a microfluidic delivery device having a housing and a microfluidic cartridge releasably connectable with the housing are provided. The microfluidic cartridge includes a reservoir for containing a fluid composition, a first face, and a second face joined with the first face. The electrical circuit has a first end portion and a second end portion. The first end portion of the electrical circuit is disposed on the first face and the second end portion of the electrical circuit is disposed on the second face. The first end portion includes electrical contacts and one or more circuit minor openings that are configured to mate with minor guideposts on the housing of a microfluidic delivery device. The microfluidic cartridge may include one or more major openings that are configured to mate with major guideposts on the housing. The microfluidic cartridge includes a microfluidic die disposed on the second face.

Abstract: Disclosed is a disposable absorbent article including two substrates; and an adhesive composition including a first polymer that is propylene-based and has a Mw of no greater than about 75,000, and a second polymer that is propylene-based and has a Mw of at least about 100,000, where the adhesive composition is used for at least two applications in the disposable absorbent article and is delivered via a molten bulk tank.

Abstract: A wound dressing comprising a mat of gel forming fibers comprising silver, the mat having an open structure reinforced with textile fibers or threads, or fibers or threads of limited absorbency for use in the treatment of wounds.

Abstract: A methods and mixtures are provided for sterilization of a polymerizable monomer, in which the mixture contains at least the polymerizable monomer, a compound (a), and a compound (b). Compound (a) is selected from the group of compounds (a1), compounds (a2), and compounds (a3), wherein compounds (a1) are represented by general formula (I): wherein R1, R2, R3, and R4, independent of each other, represent a substituted alkyl residue, a non-substituted alkyl residue, a halogen, a nitro group, or a cyano group; compounds (a2) are selected from the group of dimers of compounds (a1); and compounds (a3) are selected from the group of dialkyldicarbonates. Compound (b) is selected from the group of water and alcohols.

Abstract: The invention concerns a medical or veterinary device comprising a covalently immobilized and cross-linked agarose coating, a method for the production of same and a cross-linked agarose coating.

Abstract: Electrically conducting, biocompatible, biodegradable tissue growth comprising graphene flakes in a polymeric matrix are provided.

Abstract: A solid state method of producing inorganic nanoparticles using glass is disclosed. The nanoparticles may not be formed until the glass is reacted with or degraded by contact with a fluid in vivo or in vitro.

Abstract: The present invention provides a dry powder that is suitable for use in forming a hydrogel and characterized by a stable composition at ambient conditions. The dry powder includes a prepolymer including a straight chain polyethylene glycol, and a thermally activated free radical initiator selected from the group consisting of sodium persulfate, potassium persulfate, and ammonium persulfate. The present invention also provides a method of forming the dry powder, and a method of preparing a hydrogel where a reaction mixture is formed including the dry powder and a buffered aqueous solution.

Abstract: The present invention provides an orthopedic implant including a base device having a device surface and a fixation material attached to at least one portion of the device surface. The fixation material is configured to provide a minimally sufficient adhesive force to resist natural pull out caused by forces acting on the base device after implantation and bone growth. Also provided is a method of manufacturing an orthopedic implant. A base device with a device surface is provided and a minimally sufficient adhesive force, that can resist natural pull out caused by forces acting on the base device after implantation and bone growth, is determined. A proper amount of fixation material sufficient to provide an adhesive force equal to the minimally sufficient adhesive force is determined and fixation material is applied to the device. When the proper amount of fixation material is applied to the device surface, application is stopped.

Abstract: Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

Abstract: The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.